GENB
NASDAQGenerate Biomedicines Inc.
Price$12.55+0.42 (+3.42%)
01:30 PM03:45 PM
News · 26 weeks30-25%
2025-12-072026-05-31
Mix1490d
- Analyst6(43%)
- Other3(21%)
- Insider2(14%)
- SEC Filings2(14%)
- Offering1(7%)
Latest news
25 items- PRGenerate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare ConferenceSOMERVILLE, Mass., May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ:GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026. A live webcast is expected to be available in the Events and Presentations section of the Company's investor website at investors.generatebiomedicines.com. An archived replay is also expected to be available following the presentation.About Generate:BiomedicinesGenerate (NASDAQ:GENB) is a clinical-stage generative biology company founded at the intersection of machine le
- SECSEC Form SCHEDULE 13G filed by Generate Biomedicines Inc.SCHEDULE 13G - Generate Biomedicines, Inc. (0002100782) (Subject)
- SECSEC Form SCHEDULE 13G filed by Generate Biomedicines Inc.SCHEDULE 13G - Generate Biomedicines, Inc. (0002100782) (Subject)
- PRGenerate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business UpdateSOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advanceClinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026 SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ:GENB) ("Generate") today reported financial results for the first quarter ended March 31, 2026,
- SECSEC Form 10-Q filed by Generate Biomedicines Inc.10-Q - Generate Biomedicines, Inc. (0002100782) (Filer)
- SECGenerate Biomedicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Generate Biomedicines, Inc. (0002100782) (Filer)
- ANALYSTH.C. Wainwright initiated coverage on Generate Biomedicines with a new price targetH.C. Wainwright initiated coverage of Generate Biomedicines with a rating of Buy and set a new price target of $16.00
- ANALYSTPiper Sandler initiated coverage on Generate Biomedicines with a new price targetPiper Sandler initiated coverage of Generate Biomedicines with a rating of Overweight and set a new price target of $24.00
- ANALYSTMorgan Stanley initiated coverage on Generate Biomedicines with a new price targetMorgan Stanley initiated coverage of Generate Biomedicines with a rating of Overweight and set a new price target of $20.00
- ANALYSTCantor Fitzgerald initiated coverage on Generate BiomedicinesCantor Fitzgerald initiated coverage of Generate Biomedicines with a rating of Overweight
- ANALYSTGuggenheim initiated coverage on Generate Biomedicines with a new price targetGuggenheim initiated coverage of Generate Biomedicines with a rating of Buy and set a new price target of $30.00
- ANALYSTGoldman initiated coverage on Generate Biomedicines with a new price targetGoldman initiated coverage of Generate Biomedicines with a rating of Buy and set a new price target of $26.00
- INSIDERNew insider Pioneering Medicines 02, Llc claimed ownership of 1,562,500 shares (SEC Form 3)3 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERChief Executive Officer Nally Michael bought $240,000 worth of shares (20,000 units at $12.00), increasing direct ownership by 4% to 572,707 units (SEC Form 4)4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERSEC Form 4 filed by Director Vessey Rupert4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERChief People Officer Grous Beth bought $4,800 worth of shares (300 units at $16.00) (SEC Form 4)4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERSEC Form 4 filed by Director Arnold Frances4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERSEC Form 4 filed by Chief Legal Officer & GC Martin Sean4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Lee Laurie Anne4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERSEC Form 4 filed by Director Simonian Nancy A4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERPresident & CFO Silvers Jason bought $32,000 worth of shares (2,000 units at $16.00) (SEC Form 4)4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERDirector Afeyan Noubar converted options into 32,969,159 shares and bought $75,000,000 worth of shares (4,687,500 units at $16.00) (SEC Form 4)4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERSEC Form 4 filed by Chief Technology Officer Grigoryan Gevorg4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERChief Executive Officer Nally Michael converted options into 658,327 shares (SEC Form 4)4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- INSIDERDirector Bancel Stephane converted options into 724,160 shares (SEC Form 4)4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
GENB FAQ
6 questionsWhere does GENB stock trade?
Generate Biomedicines Inc. (GENB) is listed on NASDAQ.What sector and industry is GENB in?
Generate Biomedicines Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Generate Biomedicines Inc. go public?
Generate Biomedicines Inc. (GENB) completed its IPO in 2026.What are analysts saying about GENB?
Generate Biomedicines Inc. has had 6 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1600.00 price target on 2026-04-13. Recent price targets range from $1600.00 to $3000.00.What companies are similar to GENB?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GENB side-by-side with any of them on Quantisnow.How can I track GENB on Quantisnow?
Quantisnow aggregates Generate Biomedicines Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GENB to receive live email and push alerts on every new disclosure.